Studies of the Prevention of Atrial Fibrillation by ALA
Study Details
Study Description
Brief Summary
An alpha-linolenic acid (ALA) rich diet in the Lyon Heart Study reduced sudden cardiac deaths possibly by reducing cardiac arrhythmias and ventricular fibrillation (Lancet 1994). Since then, there has been a growing interest in ALA as a cardioprotective nutrient. Much of the interest has focused on the potential antiarrhythmic effect of ω-3 fatty acids, especially the longer chain ω-3 fatty acids, DHA and EPA, derived from fish. We therefore concluded it important to test whether the shorter chain ω-3 vegetable oil ALA also had antiarrhythmic effects, since this might also explain the beneficial effects seen on cardiovascular mortality in the Lyon Heart Study.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Objective: We determined the effect of an ALA rich diet in reducing recurrence of atrial fibrillation as a further example of a cardiac arrhythmia.
Design: Randomized parallel design efficacy study. Setting: Three university hospital centers in the Bordeaux region, France. Patients: 98 successive patients successfully underwent electro cardioversion of whom 75 completed the study without major deviations according to the protocol.
Intervention: A canola margarine and oil together with a Mediterranean diet (ALA ω-3, 1.4 g/d) versus a conventional diet (control), with a one year follow-up.
Main outcome measure: Length of time to first recurrence of atrial fibrillation.
Significance: If ALA is antiarrhythmic this action may explain its cardioprotective effect in clinical trials and cohort studies.
Study Design
Outcome Measures
Primary Outcome Measures
- rate of recurrence and length of time to first recurrence of atrial fibrillation. []
Eligibility Criteria
Criteria
Inclusion Criteria:
- patients hospitalized in one of the three centers in the Bordeaux region, and who subsequently underwent successful electrocardioversion for atrial fibrillation.
Exclusion Criteria:
-
included patients who were unable to receive electrocardioversion or those who were already enrolled in another trial
-
patients who were unable or unwilling to comply with the diet recommendations (experimental or control) or follow-up requirements
-
patients with clinically significant cardiac disease, advanced heart failure, cardiac cachexia, thyroid disease, treated or untreated, clinically significant hepatic or renal disease or a history of malignant disease or alcohol abuse were not included
-
Taking ALA rich foods or recording intakes of ALA >2g/d on the control diet or reporting using <1g/d on the ALA diet was considered a major deviation from the protocol.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Emile Roux Hospital | Paris | France | 94456 |
Sponsors and Collaborators
- University of Toronto
- University Hospital, Bordeaux
- Institut National de la Santé Et de la Recherche Médicale, France
Investigators
- Principal Investigator: Serge Renaud, MD, PhD, Emile Roux Hospital, A.P.H. Paris, 94456 Limeil-Brevannes, France
Study Documents (Full-Text)
None provided.More Information
Publications
- 99-04 (CPPRB Bordeaux B)